ContraFect Corporation is a US-based clinical-stage biotechnology firm focused on developing life-saving protein and antibody-based products for the treatment of drug-resistant infections. The company's lead product, Exebacase, is undergoing Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. ContraFect Corporation also offers other anti-bacterial therapeutic options, including CF-296 and CF-370, which are in various stages of development.